Life Sciences

Unique Risks and Rewards

'; } else if (is_page(array(116,114))){ echo '

SOFTWARE AND WEB

'; } else if (is_page(array(197, 199, 450))) { echo '

EXPERTS IN LEGISLATIVE AND PUBLIC POLICY MATTERS

'; } ?>
  • About Us
    • 0, 'show_date' => '', 'date_format' => get_option('date_format'), 'child_of' => 0, 'exclude' => '61', 'include' => '', 'title_li' => '', 'echo' => 1, 'authors' => '', 'sort_column' => 'menu_order', 'link_before' => '', 'link_after' => '', 'walker' => '' ); //$pages = get_pages($args); wp_list_pages( $args ); } //print_r($pages); ?>

Representative Matters and Accomplishments

  • Representative MattersLead Attorney and Key Business Advisor for Global Public Health During H1N1 Pandemic: global business strategy, transactional support (IP in-licensing and collaborations, out-licensing and sales agreements), regulatory (including FDA) and legislative matters for the commercialization or development of reagent and instrument products to identify or detect H1N1 isolates in support of public health organizations and laboratories world-wide.
  • Drafted language that was incorporated into key sections of P.L. 109-417, the Pandemic All-Hazards Preparedness Act, which provides transactional authority and funding for the development, commercialization and stockpiling of vaccines, therapeutics and diagnostics to prevent, diagnose or treat pandemic influenza and other infectious diseases.
  • Negotiated a scientific collaboration agreement with a non-profit commercial entity and an academic institution to jointly develop, validate, obtain regulatory approval for and sell a real-time PCR assay for the diagnosis of certain types of infections.
  • Negotiated a collaboration with a next tier up subcontractor and a prime contractor to provide real time PCR assays for use in the U.S. Postal Service’s Biohazard Detection System.
  • Chaired the capture team in obtaining and negotiating a “commercial services” contract (under FAR Subpart 12) valued at $24.5 million with a U.S. military agency for the development of a point of care benchtop medical device and assay panel for the identification of certain pathogens.
  • Subscription license that authorized the National Institutes of Health to use Celera’s proprietary genomic and proteomic databases and software research tools for research and for the generation of U.S. Government intellectual property.
  • Strategic alliance with a European company to develop, co-market and deliver new bioinformatics software tools that integrated the company’s automated genome annotation, comparison and expression analysis software with Celera databases.
  • Scientific collaboration with genomics dataset and bioinformatics software tool provider to develop a new database product which applied the collaborator’s proprietary protein structure/function prediction technology to our client’s proprietary mammalian sequences and other public domain sequences in order to create a comprehensive, genome-wide assignment of protein function, which included an agreement that enabled the parties to co–market the new database.